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Changes in CF Descriptive Terminology
Attempts to classify individuals with CF based on sweat chloride values are not as useful as was envisioned originally.80 CF lung disease,
the main cause of morbidity and mortality, has been identified in every group. Furthermore, patients diagnosed with CF as newborns
who then receive the recommended specialized care may have a delay in pulmonary involvement for decades. Thus, such classification
schemes as “atypical” or “typical,” “mild” or “severe,” and “classical” or “nonclassical” are not recommended. The authors recognize
that some of these terms are embedded in the literature and that NBS programs will continue to use “classical” and “atypical,” but as
time passes the clinical distinctions will not be sharp enough to sustain such terminology. Although once considered an unambiguous
disease entity resulting in death in early childhood, CF is now known to cause a wide spectrum of disease, and determining an individual’s
prognosis is not possible using currently available tools. In fact, individuals who initially display few deleterious health effects can
develop severe disease in 1 or more organ systems. Therefore, careful monitoring and timely treatment are crucial for all affected
individuals.
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Abstract
Newborn screening (NBS) for cystic fibrosis (CF) is increasingly being implemented and is soon
likely to be in use throughout the United States, because early detection permits access to specialized
medical care and improves outcomes. The diagnosis of CF is not always straightforward, however.
The sweat chloride test remains the gold standard for CF diagnosis but does not always give a clear
answer. Genotype analysis also does not always provide clarity; more than 1500 mutations have been
identified in the CF transmembrane conductance regulator (CFTR) gene, not all of which result in
CF. Harmful mutations in the gene can present as a spectrum of pathology ranging from sinusitis in
adulthood to severe lung, pancreatic, or liver disease in infancy. Thus, CF identified postnatally must
remain a clinical diagnosis. To provide guidance for the diagnosis of both infants with positive NBS
results and older patients presenting with an indistinct clinical picture, the Cystic Fibrosis Foundation
convened a meeting of experts in the field of CF diagnosis. Their recommendations, presented herein,
involve a combination of clinical presentation, laboratory testing, and genetics to confirm a diagnosis
of CF.
Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in the
United States, occurring in approximately 1 in 3500 newborns.1–3 Treatment advances over
the past several decades have raised the median predicted survival age in the United States
from the mid-teens in the 1970s to more than 36 years old today;4 optimal outcomes depend
on timely and accurate diagnosis, however.5–8 Although the vast majority of persons with CF
are diagnosed through classic signs and symptoms of the disease (Table I) and corroborative
laboratory results, the diagnosis is not as clear-cut in approximately 5% to 10% of individuals
with CF.4,9–11 To facilitate the diagnostic process and thereby improve access to vital medical
services, in 1996 the Cystic Fibrosis Foundation convened a panel of experts to develop criteria
for the diagnosis of CF. The panel’s consensus was that the diagnosis of CF should be based
on the presence of 1 or more characteristic clinical features, a history of CF in a sibling, or a
positive newborn screening (NBS) test, plus laboratory evidence of an abnormality in the CF
transmembrane conductance regulator (CFTR) gene or protein.12 Acceptable evidence of a
CFTR abnormality included biological evidence of channel dysfunction (ie, abnormal sweat
chloride concentration or nasal potential difference) or identification of a CF disease-causing
mutation in each copy of the CFTR gene (ie, on each chromosome). Nevertheless, some patients
remain difficult to classify due to the presence of only limited clinical features of CF and
inconclusive diagnostic test results.
The significant advances in the diagnosis and treatment of CF over the past decade have
increased our understanding of the disease, making this an opportune time to reexamine the
criteria for a diagnosis of CF. For example, the age of onset of symptoms is increasingly
recognized as being highly variable, ranging from prenatal evidence of echogenic bowel to
onset of symptoms in late adolescence or adulthood that nevertheless can cause major
morbidity and premature mortality. Our knowledge of the scope and complexity of CFTR gene
mutations also has expanded greatly. In 1996, approximately 500 mutations had been
identified, with typical commercial panels screening for only 30 of them. Today, more than
1500 mutations have been identified (http://www.genet.sickkids.on.ca/cftr), and
comprehensive analysis of the CFTR gene, including sequence determination of the exons and
intron splice sites, as well as detection of gross deletions and duplications, is readily available.
Extensive genetic studies have produced both greater awareness of the spectrum of mutations
in specific population groups13 and increased understanding of genotype–phenotype
relationships,14,15 illuminating distinctions between CFTR mutations with limited or no
functional effects and those known or predicted to cause CF disease. For the purposes of this
article, here “CF mutation” refers only to a CF disease-causing mutated allele, although it is
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recognized that mutations in the CFTR gene can result in various pathologies, ranging from
chronic sinusitis16 to extensive hepatobiliary17 and lung disease.15 Our increased
understanding of the wide range of phenotypes in individuals diagnosed with CF is helping to
establish a breakpoint for the diagnosis of CF. In addition to the progress in these areas,
important advances in defining reference and abnormal ranges of sweat chloride concentrations
more clearly also may help improve the accuracy of CF diagnosis.
One of the greatest changes over the past decade has been the way in which individuals with
CF come to recognition. In 1996, most people in the United States who presented for diagnostic
testing did so based on clinical features or a positive family history; at the time, NBS for CF
was routinely operational in only 2 states. Today, CF NBS is in various stages of
implementation in 40 states and is likely to be implemented in all states by 2010. Such
widespread NBS is rapidly changing the diagnostic paradigm. In contrast to individuals who
are diagnosed due to clinical features suggestive of CF, infants referred for diagnostic testing
after a positive screen, though they may be underweight,18 often have no clear clinical
manifestations of the disease. NBS for CF depends instead on the initial identification of high
values of immunoreactive trypsinogen (IRT) in the blood of the newborn (Figure). Because
normal IRT reference values vary slightly, the individual NBS program in the state in which
the newborn is being tested sets the specific cutoff value that defines an elevated IRT. After
an abnormal IRT value is identified, most NBS programs perform DNA testing to identify
known CFTR gene mutations (IRT/DNA strategy), while other programs repeat the IRT
measurement in a second blood sample obtained from the infant at age approximately 2 weeks
(IRT/IRT strategy).19 Both strategies have been reported to provide approximately 90% to
95% sensitivity,20,21 and both identify newborns at risk for a wide spectrum of disease
severity.22,23
CF NBS is a screen, not a diagnostic test, and thus identifies only newborns at risk for CF. A
positive screening result, indicating persistent hypertrypsinogenemia, must be followed by
referral for direct diagnostic testing (ie, sweat chloride test) to confirm a diagnosis of CF. With
sufficient experience, sweat testing can be performed adequately in infants, but interpreting
the results can be problematic. Some infants have been particularly difficult to classify, such
as those with 2 CF mutations and a sweat chloride value <40 mmol/L and those with only 1
CF mutation and a slightly elevated sweat chloride value. Although such infants represent only
a small fraction of patients, they may be at risk for developing complications of CF and thus
should be identified and followed.
The opportunity provided by NBS to diagnose individuals before symptoms appear and the
ability to apply recently acquired knowledge of CF genotype and phenotype relationships to
the diagnostic process clearly demonstrate the need for an improved algorithm for diagnosis.
Toward this end, in 2007 the Cystic Fibrosis Foundation convened another diagnosis consensus
committee of experts, including some members of the panel from 1996 together with
representatives from the United States, Canada, Europe, and Australia. In addition to
addressing the needs of the clinician faced with the infant with a positive screen, the meeting
also provided an opportunity to apply the newly acquired tools to older patients with diagnostic
uncertainty. This article presents consensus recommendations for a diagnosis of CF developed
by the committee after reviewing recent data, including a diagnostic algorithm formulated by
an international group of experts following a European consensus conference.10 In addition,
it is intended to present guidance to physicians who are faced with disorders that are related to
the partial loss of CFTR function but do not clearly meet the diagnostic criteria for CF. In the
end, the diagnosis of CF must be based on good clinical judgment and, in rare cases, may
become apparent only over time.
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The measurement of sweat electrolyte concentrations has been the mainstay of diagnosing CF
since a standardized procedure, known as the Gibson-Cooke method, was established in
1959.24 Subsequent analysis of isolated single sweat ducts identified chloride as the principle
electrolyte affected in CF.25 The discovery of CFTR confirmed the role of electrolyte transport
in the etiology of CF and gave a molecular rationale to the sweat test for diagnosing CF.
Although the ability to test for CFTR gene mutations gives a new dimension to diagnosing CF,
the sweat chloride test remains the standard procedure to confirm a CF diagnosis.
Test Methodology
Appropriate performance of the sweat test is crucial for the accurate diagnosis of CF. Therefore,
the Cystic Fibrosis Foundation requires that sweat testing conducted at accredited CF care
centers adheres to the standards recommended by a Cystic Fibrosis Foundation committee
comprising CF center directors.26 The sweat test involves transdermal administration of
pilocarpine by iontophoresis to stimulate sweat gland secretion, followed by collection and
quantitation of sweat onto gauze or filter paper or into a Macroduct coil (Wescor Inc, Logan,
Utah) and analysis of chloride concentration, as described by the Clinical Laboratory Standards
Institute.27 Laboratories accredited by the College of American Pathologists also must follow
the procedures and protocols outlined in the College’s Laboratory Accreditation Program
Inspection Checklist.28 Because of the additional technical challenges involved in obtaining
sweat from newborns, CF NBS algorithms, under local public health department regulations,
often recommend that NBS-positive newborns undergo sweat testing only at a Cystic Fibrosis
Foundation– certified laboratory.
Details on performing the sweat test can be found in the aforementioned documents. The Cystic
Fibrosis Foundation’s diagnosis consensus committee highlighted some important aspects of
sweat testing:
1. To increase the likelihood of collecting an adequate sweat specimen, it is
recommended that sweat chloride testing in asymptomatic newborns with a positive
CF NBS first be performed when the infant is at least 2 weeks of age and weighs >2
kg.29 In symptomatic newborns (eg, those with meconium ileus), sweat chloride can
be evaluated as early as 48 hours after birth if adequate sweat can be collected,26,27
although the likelihood of inconclusive results may be greater at this age.29 A
sufficient sweat volume is defined as at least 75 mg of sweat obtained by the Gibson-
Cooke method or at least 15 μL obtained by the Macroduct coil collection method.26
2. Laboratories performing sweat testing should maintain an “insufficient sweat
volume” collection rate of <5% for infants over age 3 months. Some data suggest that
infants under age 3 months may be at greater risk for insufficient sweat volume
collection,30 but this issue requires further investigation with different sweat
collection methods before a standard recommendation can be established. Factors that
influence sweat volume include age, sex, body weight, race, condition of the skin,
and collection system used.29
3. Sweat chloride is the only analyte on which a diagnosis of CF should be based.
4. The sensitivity of chloride detection should be validated by the laboratory. The
analytical method should be able to accurately detect sweat chloride at the lower end
of the normal range (10 mmol/L) without the addition of extraneous chloride to
artificially “boost” the sensitivity.
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5. Sweat conductivity or osmolality should not be used for diagnosing CF at the present
time. Although determining sweat conductivity by the Nanoduct device (Wescor Inc)
may prove to be useful someday,31,32 so far it has produced a high rate of false-
negative results.33 Currently, insufficient data are available on which to base a
recommendation for its use in diagnosing CF.
6. Bilateral testing is suggested as a useful means of ensuring that at least 1 adequate
sweat sample is obtained (although inadequate samples from 2 sites should never be
pooled for analysis). The analysis of 2 separate samples from bilateral collection also
could increase the reliability of the result, although it does not provide a substitute for
a second sweat test, which is required sometimes.34
7. It is important that the laboratory performs the sweat collection and analysis on the
same day and reports the results and their interpretation to clinicians and parents
expeditiously. Standard procedure should be to perform the analysis within a few
hours after collection. Although sweat collected in gauze, once reweighed and secured
in a vial with a tightly fitting lid, has been shown to be stable for up to 72 hours at 4°
C,35 storage time and conditions must be validated for stability by each laboratory
individually. Validation of storage is especially important when the Macroduct system
is used, because the stability of sweat collected in Macroduct coils has not yet been
established.
Test Interpretation
Since the introduction of the original standardized sweat test methodology, universal
definitions of normal (≤39 mmol/L), intermediate (40 to 59 mmol/L), and abnormal (≥ 60
mmol/L) sweat chloride values have been applied to all patients regardless of age (see below).
This classification of sweat chloride ranges was initially affirmed through an examination of
7200 sweat tests performed between 1959 and 1966.36 Like most published reports of sweat
chloride values, the technical aspects of the sweat test methodologies would not meet currently
accepted guidelines, and the studies lacked truly healthy controls, making it difficult to derive
a valid reference interval.37 But despite these limitations, the traditionally accepted sweat
chloride reference range has generally proven satisfactory. In the 2005 Cystic Fibrosis
Foundation Patient Registry, only 3.5% of patients with a diagnosis of CF had a sweat chloride
value <60 mmol/L, and only 1.2% had a value <40 mmol/L.4
Although such traditionally accepted sweat chloride ranges appear to be adequate for
diagnosing CF in children presenting with pancreatic exocrine insufficiency and suppurative
lung disease, an increasing number of children are being identified as being at risk for CF in
other ways. As NBS for CF becomes more widespread, it is anticipated that up to 90% of
infants with CF, who frequently have no apparent symptoms of the disease, will be detected
by age 6 weeks,38 creating an urgent need for an accurate reference range for sweat chloride
in this age group.
Sweat Chloride Values in Infancy
Studies of sweat chloride testing in infants have demonstrated that the age at which testing is
done is an important consideration when interpreting the sweat chloride value. Most infants
identified by NBS will undergo sweat testing after 2 weeks of age. Earlier testing could lead
to misleading results, because sweat chloride concentrations in healthy newborns gradually
decrease over the first weeks of life.30 A study in 103 infants without CF found a mean sweat
chloride value (±1 standard deviation) of 23.3 ± 5.7 mmol/L at age 3 to 7 days, decreasing to
17.6 ± 5.6 mmol/L by age 8 to 14 days and then to 13.1 ± 7.4 mmol/L after age 6 weeks.29
This gradual early decline in sweat chloride values suggests that sweat test results are less likely
to be difficult to interpret after age 2 weeks. In a small number of individuals, sweat chloride
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values remain inconclusive for months or even years. Although extensive longitudinal data on
sweat chloride testing in individuals age 2 weeks and older are not available, 1 small study
compared sweat chloride values in 43 F508del (also known as ΔF508) heterozygous infants at
age 6 weeks and again at age 6 to 12 months and found both increases and decreases in sweat
chloride values between the 2 time points.39 Indeed, 2 infants with sweat chloride values of
40 to 50 mmol/L at age 6 weeks exhibited values in the clearly diagnostic range (≥60 mmol/
L) when tested again at age 12 months. This indicates that repeat sweat testing is sometimes a
necessary component of accurate diagnosis.
Reference values for sweat chloride in the first 3 months of life have largely been determined
from a detailed study of 725 infants identified as being at risk through NBS or based on clinical
presentation who carried 0, 1, or 2 copies of the common CFTR gene mutation F508del.40 All
of the infants underwent a standardized sweat chloride test following methodology that meets
current published guidelines. The infants without a CF phenotype and without F508del (n =
184) had a mean sweat chloride value of 10.6 ± 5.6 mmol/L; notably, only 1 of these infants
had a sweat chloride value >30 mmol/L. Those infants who did not have a CF phenotype but
were heterozygous for F508del (n = 128) had a mean sweat chloride value of 14.9 ± 8.4 mmol/
L, or 1 SD above the mean for those infants who did not carry F508del; 9 of these infants had
a sweat chloride value >30 mmol/L. Although no systematic follow-up of these infants was
conducted to determine whether any could be diagnosed with CF, no cases of CF emerged
from this cohort in the subsequent 10 years. Thus, it can be concluded that sweat chloride values
>30 mmol/L can occur in healthy individuals who are heterozygous for F508del. All of the
F508del homozygous infants had sweat chloride concentrations >60 mmol/L. The findings
from this study have been supported by similar findings in studies from Australia41 and
Massachusetts.30
Although sweat chloride values are generally ≥60 mmol/L in infants with CF, lower values
also can occur.1,19,30,40,42–45 In a 4-year cohort of infants detected through the
aforementioned Massachusetts NBS program who had clinician-diagnosed CF, 9 of 110 (8.2%)
had a sweat chloride concentration of 30 to 59 mmol/L. and 3 of 110 (2.7%) had a concentration
<30 mmol/L.11 The findings from this small but significant population lend further support to
our recommendation (Figure) that a sweat chloride value ≥ 30 mmol/L in infants <age 6 months
should be considered abnormal and trigger further patient evaluation.29,32,40–45
Recommended Sweat Chloride Reference Values in Infancy
Based on the available data on sweat chloride test results in healthy and CF-affected infants,
the consensus committee recommends the following sweat chloride reference ranges for infants
up to age 6 months: ≤29 mmol/L, CF unlikely; 30 to 59 mmol/L, intermediate; ≥60 mmol/L,
indicative of CF (Figure). As more data emerge from NBS programs, the upper limit of the
normal reference range may have to be lowered. Individuals with intermediate results should
undergo repeat sweat chloride testing and then be referred to a CF center with expertise in
diagnosing CF in infancy. Further evaluation should include an early detailed clinical
assessment, more extensive CFTR gene mutation analysis, and repeat sweat chloride testing
and follow-up at 6- to 12-month intervals until the diagnosis is clear.
Sweat Chloride Values Beyond Infancy
In addition to the burgeoning group of infants identified as at risk for CF through NBS,
increasing recognition of the great variations in symptomatology of the disease is increasing
the numbers of older children, adolescents, and adults in whom the diagnosis is being
considered, including many with an indistinct CF phenotype. Clear sweat chloride reference
intervals are required, but studies of normal sweat chloride values beyond infancy using current
standardized testing procedures remain limited. One study in unaffected adults age 18 to 39
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years found moderately elevated sweat chloride levels (average, 31 mmol/L; range, 14 to 48
mmol/L).46 A more rigorous study of sweat chloride values in 282 carefully screened healthy
individuals age 5 to 68 years was recently completed in Australia.47 This study demonstrated
that although the median sweat chloride value in each of the 7 age-based cohorts of volunteers
was well below the value accepted as diagnostic for CF (≥60 mmol/L), the upper limit of the
95% confidence interval was in the intermediate range (40 to 59 mmol/L) for those over age
15 years and just under 60 mmol/L for those age 20 to 68 years, none of whom carried the
F508del mutation. Three healthy subjects age 15 years and older had a sweat chloride value
>60 mmol/L. These findings suggest that sweat chloride analysis alone may not be used to
diagnose CF.
Although it is apparent that sweat chloride values ≥40 mmol/L can occur in individuals without
CF, intermediate sweat chloride values (40 to 59 mmol/L) as well as, rarely, sweat chloride
values <40 mmol/L also can occur in individuals with CF.48–51 In a Canadian study, sweat
chloride values <60 mmol/L were observed in 5 of 24 patients (21%) with pancreatic-sufficient
CF.52 Individuals diagnosed with CF as adults also have lower sweat chloride values;53 a
study of the Cystic Fibrosis Foundation Registry found that 13.85% of individuals diagnosed
with CF as adults had a value <60 mmol/L.48 Increasing recognition of the wide range of CF
phenotypic variability54,55 should lead to increasing diagnosis of CF in individuals with
intermediate sweat chloride values. These data add support to our recommendation that sweat
chloride values ≥40 mmol/L in individuals over age 6 months should be considered beyond
the normal range and merit further evaluation, to include repeat sweat chloride testing and
DNA analysis for CFTR mutations as described later.
Recommended Sweat Chloride Reference Values Beyond Infancy
Based on the available data on sweat chloride test results beyond infancy, the consensus
committee recommends the following sweat chloride reference ranges for individuals over age
6 months: ≤39 mmol/L, CF unlikely; 40 to 59 mmol/L, intermediate; ≥60 mmol/L, indicative
of CF. Individuals with intermediate results should undergo repeat sweat chloride testing and
further evaluation, including detailed clinical assessment and more extensive CFTR gene
mutation analysis. Clinical follow-up should occur at 6-to 12-month intervals, and repeat sweat
chloride testing should be performed periodically, particularly if a change in symptoms occurs,
until the diagnosis is clear.
Role of DNA Analysis in CF Diagnosis
For the vast majority of persons with CF, the sweat chloride test remains the best diagnostic
indicator. For those individuals with sweat chloride values in the intermediate range, DNA
analysis can help establish the diagnosis.3 The analysis and interpretation of CF genotype
information requires the use of appropriate testing techniques to identify CFTR mutations,
standardized criteria for defining a CF-causing mutation, and an understanding of the
contribution of the genetic background to the phenotypic variability of CF. It should be noted
that 2 or more CFTR mutations detected in genomic DNA may be located in trans on 2 separate
chromosomes or in cis on the same chromosome. The latter situation is not generally associated
with disease. This distinction is not made in most commercial laboratories, however, and
throughout the rest of the article, we assume that the trans arrangement applies.
Despite the potential usefulness of the information, acquiring a CF genotype can be difficult.
Although currently available mutation screening panels can identify 90% of CFTR mutations,
9.7% of genotyped individuals in the Cystic Fibrosis Foundation Patient Registry have at least
1 un-identified mutation.4 Even commercially available “sequencing” tests provide
information only about the coding region of the gene and the immediately adjacent intron
sequences; large deletions or insertions and many RNA processing or transcriptional mutations
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are not readily identified. Identification of CF mutations is more challenging in some
populations; for example, the nature, distribution, and frequency of CF-causing mutations in
populations with Hispanic, African, or Asian origins differ markedly from those identified in
Caucasians. Thus, for instance, the screening panel of CFTR mutations recommended by the
American College of Medical Genetics (ACMG), which was developed for population or
prenatal screening of Caucasians, detects only 68.5% of CF-causing mutations in the Hispanic
population.56
Even if the genotype is identified, the consequences of the vast majority of CFTR mutations
remain unknown. A mutation is simply a change from the accepted normal sequence of the
gene and its control elements. To be considered a cause of CF, the mutation must:
1. Cause a change in amino acid sequence that severely affects CFTR synthesis or
function; or
2. Introduce a premature termination signal; or
3. Alter invariant nucleotides of intron splice sites; or
4. Cause a novel amino acid sequence that does not occur in the normal CFTR genes
from at least 100 carriers of CF mutations from the patient’s ethnic group.
Of the 1547 mutations currently listed in the CF Mutation Database
(http://www.genet.sickkids.on.ca/cftr/app), 225 are designated as sequence variants with no
resulting clinical effect. Of the remaining 1322 potential CF-causing mutations, only 23 (Table
II) have been demonstrated by direct or empirical evidence to cause sufficient loss of CFTR
function to confer CF disease and thus can be recommended as conclusive genetic evidence
for diagnostic purposes. These mutations account for the defects in both CFTR genes in 85%
of the CF population; the severe loss of CFTR function in these individuals usually results in
pancreatic insufficiency (PI) and pulmonary complications. Many of the remaining 15% of
individuals with CF have mutations with unknown effects on CFTR function. The Cystic
Fibrosis Foundation is considering the feasibility of characterizing these CFTR mutations to
determine the molecular basis for their effects on cell function. The knowledge gained should
help scientists determine the usefulness of new targeted therapies that may potentiate channel
performance or correct protein trafficking in individuals carrying these mutations, as well as
aid diagnosis. As our understanding of the effects of different CFTR mutations develops, the
list of mutations that provide acceptable diagnostic evidence will need to be expanded. In the
meantime, extensive genetic analysis to identify large deletions or other obviously destructive
mutations may be useful in resolving the diagnosis in individual cases.
Because the effects of many mutations remain obscure, and because some allow pancreatic
sufficiency (PS) due to a slight degree of residual chloride channel function, some individuals
with these mutations can remain undiagnosed until adulthood. It may be difficult to distinguish
these individuals from those with disease in single organs (eg, congenital absence of the vas
deferens, idiopathic pancreatitis, various sinopulmonary disorders), who carry a higher
frequency of CFTR gene mutations than the general population.16,57,58 An example of the
complexity of mutation analysis is found in the evolving picture of individuals who are
compound heterozygotes for a CF-causing mutation and the R117H mutation in the CFTR
gene. The likelihood of CF in this group is driven by the length of a polythymidine tract in
intron 8 of the R117H allele. The presence of a 5T tract in the R117H background is usually
associated with CF, whereas R117H(7T) is more often associated with isolated male infertility
or pancreatitis.59 But individuals from both groups may display sweat chloride values in the
normal, intermediate, or diagnostic range,60 and some individuals with R117H(7T) can present
with CF lung disease. Thus, R117H(7T) is a mutation that when present in trans with a CF-
causing mutation, can cause a variable phenotype, ranging from normal to CF. Although the
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risk of poor outcomes should be weighed against the psychosocial risks of assigning a CF
diagnosis,61,62 infants with a known CF-causing mutation (Table II) and R117H(7T) are at
sufficiently high risk for lung disease to merit clinical monitoring in a CF care center.60,63
Some individuals with mutations in both copies of the CFTR gene who have partial phenotypes,
designated CFTR-related disorders, eventually may receive a diagnosis of CF based on current
diagnostic criteria. In others, a very mild or single system phenotype may allow definitive
exclusion of the diagnosis.52,55 In a few patients, the diagnosis of CF cannot be confirmed or
excluded. In effect, as knowledge of the range of phenotypes associated with CFTR gene
mutations has expanded, the demarcation line between patients with CF disease and those with
disorders associated with CFTR mutations has blurred. Thus, in this clinical setting, CF cannot
be diagnosed simply by the presence of 2 CFTR mutations; these 2 mutations must cause
significant loss of function to result in a CF clinical phenotype.
Regardless of the types of mutations found, with the possible exception of male infertility,
genotype analysis cannot be used to predict prognosis in individual patients with CF.64,65
Although there is a strong relationship between some mutations and pancreatic function (PI or
PS),66 the correlation is not absolute, and the relationship between genotype and pulmonary
disease is weak. Even individuals carrying identical Fdel508 mutations on both alleles can
exhibit a wide range of pulmonary function and severity of hepatobiliary disease.67 Work is
underway to identify various modifier genes that also may play a role in the disease process,
68 but the interaction between multiple modifier genes is likely to be complex, and at present,
no diagnostic inferences can be drawn as of yet. Consequently, the consensus committee
strongly recommends that caregivers avoid making prognostic predictions based on genotype
information in any individual with CF.
Role of Ancillary Tests in CF Diagnosis
Ancillary tests may help establish a diagnosis of CF either by revealing a phenotype, such as
PI, or by identifying an ion channel abnormality. Information regarding pancreatic exocrine
function is valuable for both diagnostic and treatment purposes. Assessment of pancreatic
function actually may be needed several times over an individual’s lifetime, because despite
the presence of PS in at least 25% of all individuals with CF at the time of identification by
NBS, most develop PI over time.18,22,69 A wide range of tests for assessing pancreatic
function are available, but all have at least 1 shortcoming for routine clinical testing (eg, low
specificity or sensitivity, complexity, high cost). When performed correctly, 72-hour stool
collection is very useful for determining pancreatic function and evaluating response to enzyme
therapy; however, this test is not used routinely, because of technical and logistical
complexities. Alternative screening tests measure the fecal concentration of endogenous
pancreatic enzymes. Because fecal trypsin and chymotrypsin tests may be inaccurate due to
intraluminal degradation and cross-reactivity with ingested enzymes, the highly specific
monoclonal test for fecal elastase, which is resistant to degradation, is preferred. Because of
its ease of use, this test is recommended for evaluating pancreatic function at diagnosis and for
monitoring individuals with PS.70 This test also has some significant limitations, however;
although reference values have been determined for healthy preterm and full-term infants,71
the test has not been extensively studied in infants with CF. Currently, a value of <100 μg/g in
individuals over age 2 to 3 years is considered indicative of PI. Higher values of fecal elastase
(100 to 200 μg/g) are considered indicative of loss of pancreatic function, although not
necessarily of sufficient severity to confer PI and warrant the need for pancreatic enzyme
supplementation. Because reference values for fecal elastase measured by the polyclonal
antibody test have not been established, and because the antibody displays some cross-
reactivity with ingested enzymes, this test is considered less reliable. In patients with CF who
are at least 7 to 8 years old, serum trypsinogen values also may be used to assess pancreatic
Farrell et al. Page 9













function.72,73 Pancreatic stimulation tests are not indicated for routine assessment of pancreatic
function in individuals with CF. Even though pancreatic lipase and co-lipase can be accurately
measured to assess pancreatic status, pancreatic electrolyte (principally Cl− and HCO3−) values
have not been validated, and reference values for the diagnosis of CF have not been sufficiently
established.
Additional ancillary tests are currently in use by clinicians to clarify the diagnostic status of
individuals with less CF-specific gastrointestinal or pulmonary symptomatology. The nasal
potential difference (NPD) test, which has been used in CF research for decades, has recently
been introduced to clinical practice to aid diagnosis;74 it may be particularly helpful in
individuals with inconclusive sweat chloride values.75 CF is indicated by the presence of a
high potential difference during baseline measurements plus a very low voltage response to
zero-chloride perfusate and isoproterenol. An NPD test showing a significant response to zero-
chloride perfusate containing isoproterenol may be useful in ruling out a diagnosis of CF. But
the quantitative aspects of NPD results that are clearly indicative of CF are not defined
consistently across all testing centers. Moreover, some overlap likely occurs between CF and
non-CF values for both the basal PD and response to zero-chloride and isoproterenol, analogous
to the overlap in sweat chloride values. The NPD test’s predictive capability improves
somewhat when analyses of sodium and chloride channel abnormalities are combined.
Nevertheless, to date only 12 US centers have been validated by the Cystic Fibrosis Foundation
for reproducible, accurate NPD testing using standardized procedures, and only 1 center has
sufficient expertise with infant NPD to make this test a useful adjunct to NBS.76 Properly
conducted NPD testing at a research center can provide valuable information for diagnosis
when clinical evidence is not clear-cut; however, access to the test is limited. Because there
are no clear reference values, validation studies, or standardized technical protocols for NPD
testing for diagnostic purposes, the test should be used only to provide contributory evidence
in a diagnostic evaluation.
Intestinal ion channel measurements, such as Ussing chamber measurements of CFTR function
from rectal biopsies, have no clearly established reference values and should be used for
research purposes only at present.
Diagnosis of CF: Consensus Statement
Individuals with suspected CF are identified for diagnostic evaluation from different pathways,
including prenatal screening or NBS. Diagnosis then may be made through various approaches,
depending on age, genotype, and phenotype. Until the advent of widespread NBS for CF,
suspicion for CF arose only from the appearance of symptoms or a family history of the disease.
But eventually, NBS for CF will be universal throughout the United States, and most
individuals will enter the diagnostic algorithm because of a positive NBS.
The primary test for confirming the diagnosis of CF is the sweat chloride test, performed
according to the guidelines described earlier. Any individual presenting with signs or
symptoms of CF (Table I) should undergo sweat chloride testing, regardless of the NBS results.
To increase the likelihood of a successful test in infants, a bilateral sweat chloride test should
be performed on individuals who weigh at least 2 kg, are more than 36 weeks gestation at birth,
and are at least 2 weeks of age. This section presents diagnostic process recommendations for
newborns with positive CF NBS, followed by recommendations for individuals presenting
through other means.
Recommended CF Diagnostic Process for Screened Newborns (Figure)
1. In infants with a positive NBS, a diagnosis of CF can be confirmed if the sweat
chloride value is ≥60 mmol/L. These patients are likely to experience life-threatening
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CF lung disease at varying ages. CFTR mutation assessment is recommended to help
confirm the diagnosis and reduce the risk of laboratory error if genotype was not
identified during NBS. The panel of 23 mutations recommended by the ACMG in
their revised list for population screening77 represents mutations known to cause CF
(Table II) and is reasonable for use in most states at present. In the absence of 2 CF-
causing mutations, sweat chloride testing should be repeated to ensure a correct
diagnosis.
2. A diagnosis of CF is very unlikely in infants with a sweat chloride value ≤29 mmol/
L. However, on rare occasions, infants with 2 identified CF-causing mutations can
have a normal sweat chloride value;11,51,63 these infants have CF and should be
followed in a CF care center. Analysis of maternal DNA is recommended to determine
whether the 2 mutations are present in cis or in trans and to help clarify the diagnosis.
3. Infants with a positive CF NBS result and sweat chloride values in the intermediate
range (30 to 59 mmol/L) should undergo at least a basic CFTR gene mutation
assessment (Table II) at the initial visit if it is not included in the NBS:
a. In the presence of 2 CF-causing mutations, a diagnosis of CF can be made.
Maternal DNA should be analyzed if necessary to determine whether the 2
mutations are present in cis or in trans.
b. Infants with intermediate sweat chloride values and no or 1 CF-causing
mutation cannot be diagnosed definitively with CF. This is an evolving
recommendation that will become clearer as experience with NBS
accumulates nationwide. Meanwhile, these infants are at increased risk for
CF, as demonstrated by the abnormal NBS and increased sweat chloride
value, and should be followed. Because clinical manifestations of CF can
appear in the first few weeks of life,78,79 a clinical assessment should be
performed at a CF care center by age 2 months, and the sweat chloride test
should be repeated at age 2 to 6 months; the earlier time might allow
resolution of the diagnosis for many families. The diagnosis of CF is then
made if it is supported by a preponderance of evidence from a variety of
assessments, as described later. To prevent possible cross-infection, the
infant should not be assessed in a clinic attended by individuals known to
have CF. Assessments may include the following:
• Clinical assessment, including anthropometrics, growth, and
state of the lungs
• Personal medical history
• Family history of CF and related phenotypes
• Extended genetic testing, if required
• Pancreatic function tests
• Oropharyngeal culture for CF-associated pathogens,
especially Pseudomonas aeruginosa
• Chest radiograph
• Liver function tests.
Infant pulmonary function testing, chest computed tomography (CT),
bronchoalveolar lavage, and NPD measurements are not recommended for
diagnosis in this age group. Clinical findings suggestive of CF, such as fecal
elastase values indicative of pancreatic damage (<200 μg/g) and a positive
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respiratory tract culture for CF-associated pathogens, especially P
aeruginosa, should be considered indicative of CF. The presence of
Staphylococcus aureus or Hemophilus influenzae is not a sufficient
indication for diagnosis in the absence of other features of CF. The sweat
chloride test should be repeated at age 2 to 6 months. Beyond age 6 months,
only sweat chloride values ≥40 mmol/L should be considered beyond the
normal range. The committee selected age 6 months as the time for transition
to acceptance of a higher range of normal sweat chloride values by
consensus. This choice was necessarily somewhat subjective, because very
little data are available on the normal values for this age group; data from
NBS programs are usually focused on the first few months of life.
• An increase in the sweat chloride value to ≥60 mmol/L
confirms a diagnosis of CF.
• A sweat chloride value ≤39 mmol/L after age 6 months
generally is not consistent with a diagnosis of CF, although CF
can occur in this group in rare cases.50,51,60,63
If the sweat chloride value remains in an intermediate range (ie, 40 to 59
mmol/L for individuals age 6 months and older), the child should continue
to be monitored every 6 to 12 months with clinical evaluations, repeat sweat
testing, and use of ancillary tests as appropriate. In the presence of 1 CF-
causing mutation and clinical findings suggestive of CFTR dysfunction (eg,
bronchiectasis, pancreatitis), a diagnosis of a CFTR-related disorder can be
made. Over time, further evaluation may confirm a diagnosis of CF in some
of these individuals.
Families of infants diagnosed with CF should receive appropriate education at the first
diagnostic visit, and genetic counseling should be provided. Sweat chloride testing should be
arranged for all first-degree siblings and for any half-siblings with signs or symptoms of CF
or who have 2 parents known to be carriers. In addition, genetic analysis should be provided
for these family members if the diagnosed infant demonstrates a sweat chloride value ≤59
mmol/L.
Recommended General Process for Diagnosing CF
In individuals presenting with symptoms of CF (Table I) or a positive family history, the
following diagnostic process is recommended:
1. A diagnosis of CF can be made if the sweat chloride value is ≥60 mmol/L. A second,
confirmatory sweat chloride test is recommended unless mutation analysis identifies
the presence of 2 CF-causing mutations (Table II). These patients, who may present
at any age, are likely to develop CF lung disease.
2. A sweat chloride value ≤39 mmol/L in individuals over age 6 months is not consistent
with a diagnosis of CF. CF is unlikely in this group. However, 2 identified CF-causing
mutations can occur in this group; these individuals have CF and should be followed
in a CF care center.
3. Individuals with sweat chloride values in the intermediate range (30 to 59 mmol/L
for infants under age 6 months; 40 to 59 mmol/L for older individuals) should undergo
extensive CFTR mutation analysis (ie, expanded panel of CFTR mutations, evaluation
for deletions, or gene sequencing):
a. In the presence of 2 CF-causing mutations, a diagnosis of CF can be made.
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b. Individuals with no or 1 CF-causing mutation and clinical findings
suggestive of CFTR dysfunction (ie, obstructive azoospermia,
bronchiectasis, or acute, recurrent, or chronic pancreatitis) may be diagnosed
with a CFTR-related disorder, depending on their clinical picture or family
history, and are at risk for CF. Sweat chloride testing should be repeated in
infants by age 2 to 6 months and immediately in older individuals. If sweat
chloride values remain in the intermediate range on repeat testing, then
further assessment should be performed at a CF care center that can provide
basic and ancillary testing to clarify the diagnosis, including:
• Clinical assessment
• Expanded genetic testing
• Exocrine pancreatic function tests
• Respiratory tract culture for CF-associated pathogens,
especially P aeruginosa.
Depending on clinical presentation, assessment also may include ancillary
tests, such as:
• Genital evaluation in males (ie, genital examination, rectal
ultrasound, semen analysis)
• Pancreatic imaging
• High-resolution chest CT
• Bronchoalveolar lavage, including microbiology assessment
• Pulmonary function testing (not routinely recommended in
infants at this time)
• NPD testing
• Exclusionary testing for ciliary dyskinesia and immune
deficiency.
Significant clinical signs or symptoms of CF, laboratory indication of PI, or a positive culture
for a CF-associated pathogen (especially P aeruginosa), should be considered strongly
suggestive of CF. Individuals who have sweat chloride values in the intermediate range and
exhibit no significant signs of CF should be monitored periodically for the appearance of
symptoms until the diagnosis can be ruled in or out.
CONCLUSION
The diagnostic procedures recommended herein recognize the wide possible range of disease
severity and permit some leeway in the diagnosis of an individual while still creating a threshold
for a diagnosis of CF. As was the case in 1996, the recommendations are based on the current
state of the knowledge and should be considered a “work in progress,” leaving room for
improvement resulting from increased insight into CF manifestations, genetics, and
pathobiology. Nevertheless, it is hoped that the consensus of opinion presented herein will
provide increased guidance for establishing or excluding a diagnosis of CF, thereby permitting
timely access to vital medical services and allowing the best possible outcomes for individuals
with the disease.
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The CF diagnostic process for screened newborns.
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Table I
Phenotypic features consistent with a diagnosis of CF
1 Chronic sinopulmonary disease, manifested by:
a. Persistent colonization/infection with typical CF pathogens, including Staphylococcus
aureus, nontypeable Haemophilus influenzae, mucoid and nonmucoid Pseudomonas
aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia
b. Chronic cough and sputum production
c. Persistent chest radiograph abnormalities (eg, bronchiectasis, atelectasis, infiltrates,
hyperinflation)
d. Airway obstruction, manifested by wheezing and air-trapping
e. Nasal polyps; radiographic or CT abnormalities of the paranasal sinuses
f. Digital clubbing
2 Gastrointestinal and nutritional abnormalities, including:
a. Intestinal: meconium ileus, distal intestinal obstruction syndrome, rectal prolapse
b. Pancreatic: PI, recurrent acute pancreatitis, chronic pancreatitis, pancreatic abnormalities
on imaging
c. Hepatic: prolonged neonatal jaundice, chronic hepatic disease manifested by clinical or
histological evidence of focal biliary cirrhosis or multilobular cirrhosis
d. Nutritional: failure to thrive (protein-calorie malnutrition), hypoproteinemia and edema,
complications secondary to fat-soluble vitamin deficiencies
3 Salt loss syndromes: acute salt depletion, chronic metabolic alkalosis
4 Genital abnormalities in males, resulting in obstructive azoospermia
Modified from Rosenstein B, Cutting G. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr
1998;132:589–95. Used with permission.
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Table II
Recommended panel of CF-causing mutations
Missense, deletion, stop mutations Splicing, frameshift mutations
G85E I507del R560T 621+1G>T 2789+5G>A
R117H F508del R1162X 711+1G>T 3120+1G>A
R334W G542X W1282X 1717−1G>A 3659delC
R347P G551D N1303K 1898+1G>A 3849+10kbC>T
A455E R553X 2184delA
Revised from the mutation panel for population screening for CF developed by the ACMG.77
Additional or alternative mutations present at significant frequencies in an ethnic population served by an NBS program may be added.
J Pediatr. Author manuscript; available in PMC 2010 January 25.
